- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
TMS manufacturer Neuronetics gained FDA clearance for its NeuroStar system for use in adolescents.
4 reports, 2 independent
Updated Sep 2
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 4
- Developments
- 1
- Repetition
- 75%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TMS manufacturer Neuronetics gained FDA clearance for its NeuroStar system for use in adolescents.
Who's involved
What this event is mainly aboutKeep exploring
Part of
A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.Also in this story
- A partnership with BARDA has accelerated the development of SCY-247 for the company.
- A company plans to submit regulatory applications to the FDA, EMA, and Australian TGA.
- Approval leads to procurement process initiation.
- UroGen Pharma Ltd., headquartered in Princeton, is seeking FDA approval for its products for the U.S. market.
The entities involved
-
TMS
American metadata company
-
Neuronetics, Inc.
American company
Nothing else this week.
Coverage
Newest first; wire copies grouped- Insider MonkeyNeuronetics, Inc. (STIM) Positions as Neurohealth Leader with Adolescent Breakthrough We recently compiled a list of the 13 Best Psychedelic Stocks to Invest in Now. Neuronetics, Inc. is placed sixth
- GlobeNewswireNeuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MALVERN, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology compa
- GlobeNewswireNeuroStar Announces New Publication in JAACAP Open Highlighting Treatment Efficacy in Depressed Adolescents Real-world data showing NeuroStar is effective in adolescents and young adults with depress
- GlobeNewswireNeuronetics to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call MALVERN, Pa., July 22, 2025 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technolo